Gene signature of residual risk after endocrine treatment in early-stage breast cancer

摘要

Methods described herein for determining the prognosis of endocrine alone treatment in a subject with breast cancer, the method a) provides a tumor sample for breast cancer; b) at least 40 of the tumors listed in Table 4 in a tumor sample Determining the expression level of the gene; c) comparing the expression level to the reference expression level of the gene group from a control sample from the subject cohort; and d) determining the residual risk associated with breast cancer, In this context, statistically significant differences or similarities in expression of gene groups compared to reference expression levels correspond to residual risk associated with breast cancer. [Selected figure] Figure 1-1